Lepu Biopharma Co., Ltd. (2157) has obtained marketing approval from the National Medical Products Administration in China for MEIYOUHENG (Becotatug Vedotin Injection). The treatment is described as the first EGFR-targeted antibody drug conjugate (ADC) approved in the country and is indicated for recurrent or metastatic nasopharyngeal cancer (R/M NPC).

According to disclosed information, MEIYOUHENG targets epidermal growth factor receptor (EGFR) and leverages a monoclonal antibody conjugated to a microtubulin-inhibiting payload. Clinical results for patients who progressed after at least two lines of systemic chemotherapy and PD-(L)1 inhibitor therapy showed clinically meaningful efficacy benefits with a manageable safety profile. These outcomes were presented as a late-breaking abstract at the 2025 American Society of Clinical Oncology Annual Meeting.

Additionally, combination therapy of MEIYOUHENG with PUYOUHENG (Pucotenlimab Injection) reportedly delivered a confirmed objective response rate (cORR) of 73.3% and a median progression-free survival (mPFS) of 10.9 months in patients who had failed immunotherapy and platinum-based regimens. These findings, which were revealed at the European Society for Medical Oncology Congress 2025, point to a potential treatment option for R/M NPC patients. Lepu Biopharma plans to explore additional indications to further realize the commercial potential of this newly approved ADC.